UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II

Value in health, 2010, Vol.13 (1), p.8-13

2010

Volltextzugriff (PDF)

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I

Value in health, 2010, Vol.13 (1), p.3-7

2010

Volltextzugriff (PDF)

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III

Value in health, 2010, Vol.13 (1), p.14-17

2010

Volltextzugriff (PDF)

Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever

American journal of health-system pharmacy, 2007-03, Vol.64 (6), p.637-643

2007

Volltextzugriff (PDF)

The National Program of Cancer Registries: explaining state variations in average cost per case reported

Preventing chronic disease, 2005-07, Vol.2 (3), p.A10-A10

2005

Volltextzugriff (PDF)

The Strategic Effects of Batch Processing

International economic review (Philadelphia), 2001-08, Vol.42 (3), p.697-728

2001

Volltextzugriff (PDF)

Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis

Clinical therapeutics, 2005-06, Vol.27 (6), p.960-969

2005

Volltextzugriff (PDF)

Endogeneity bias in the absence of unobserved heterogeneity

Annals of epidemiology, 2004-09, Vol.14 (8), p.561-565

2004

Volltextzugriff (PDF)

Costs and Survival of Patients with Colorectal Cancer in a Health Maintenance Organization and a Preferred Provider Organization

Medical care, 2005-10, Vol.43 (10), p.1043-1048

2005

Volltextzugriff (PDF)

The Decision to Conduct a Head-to-Head Comparative Trial: A Game-Theoretic Analysis

Medical decision making, 2007-07, Vol.27 (4), p.364-379

2007

Volltextzugriff (PDF)

Choosing the right battlefield for the war on drugs: an irrelevance result

Economics letters, 1998-04, Vol.59 (1), p.107-111

1998

Volltextzugriff (PDF)

Colorectal cancer screening attitudes and practices in the general population: a risk-adjusted survey

Journal of public health management and practice, 2005-05, Vol.11 (3), p.244

2005

Volltextzugriff (PDF)

Importance of perspective in economic analyses of cancer screening decisions

The Lancet (British edition), 2001-10, Vol.358 (9288), p.1169-1173

2001

Volltextzugriff (PDF)

Preferences and person trade-offs: forcing consistency or inconsistency in health-related quality of life measures?

Health economics, 2003-03, Vol.12 (3), p.187-198

2003

Volltextzugriff (PDF)

Does initial choice of antimicrobial therapy affect length of stay for patients with complicated intra-abdominal infections?

The American surgeon, 2005-10, Vol.71 (10), p.816-820

2005

Volltextzugriff (PDF)

Variation in Average Costs among Federally Sponsored State-Organized Cancer Detection Programs: Economies of Scale?

Medical decision making, 2002-09, Vol.22 (1_suppl), p.67-79

2002

Volltextzugriff (PDF)

Me-Too' Innovation in Pharmaceutical Markets

Forum for health economics & policy, 2009-01, Vol.12 (1)

2009

Volltextzugriff (PDF)

Me-Too' Innovation in Pharmaceutical Markets

Forum for health economics & policy, 2009, Vol.12 (5)

2009

Volltextzugriff (PDF)

The Utilization of Medicines beyond Patent Expiration

Forum for health economics & policy, 2008-11, Vol.11 (2)

2008

Volltextzugriff (PDF)

The Utilization of Medicines beyond Patent Expiration

Forum for health economics & policy, 2008, Vol.11 (9)

2008

Volltextzugriff (PDF)

Many medicare recipients lack awareness of colorectal cancer screening coverage: an opportunity for intervention?

The American journal of gastroenterology, 2001-09, Vol.96 (9), p.S274-S274

2001

Volltextzugriff (PDF)

Barriers to four colorectal cancer screening tests: Identification of knowledge concerns, attitudes and beliefs of persons at risk

Gastroenterology (New York, N.Y. 1943), 2001-04, Vol.120 (5), p.A605-A605

2001

Volltextzugriff (PDF)

Do drug formulary policies reflect evidence of value?

The American journal of managed care, 2006-01, Vol.12 (1), p.30-36

2006

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III

Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever

The National Program of Cancer Registries: explaining state variations in average cost per case reported

The Strategic Effects of Batch Processing

Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis

Endogeneity bias in the absence of unobserved heterogeneity

Costs and Survival of Patients with Colorectal Cancer in a Health Maintenance Organization and a Preferred Provider Organization

The Decision to Conduct a Head-to-Head Comparative Trial: A Game-Theoretic Analysis

Choosing the right battlefield for the war on drugs: an irrelevance result

Colorectal cancer screening attitudes and practices in the general population: a risk-adjusted survey

Importance of perspective in economic analyses of cancer screening decisions

Preferences and person trade-offs: forcing consistency or inconsistency in health-related quality of life measures?

Does initial choice of antimicrobial therapy affect length of stay for patients with complicated intra-abdominal infections?

Variation in Average Costs among Federally Sponsored State-Organized Cancer Detection Programs: Economies of Scale?

Me-Too' Innovation in Pharmaceutical Markets

Me-Too' Innovation in Pharmaceutical Markets

The Utilization of Medicines beyond Patent Expiration

The Utilization of Medicines beyond Patent Expiration

Many medicare recipients lack awareness of colorectal cancer screening coverage: an opportunity for intervention?

Barriers to four colorectal cancer screening tests: Identification of knowledge concerns, attitudes and beliefs of persons at risk

Do drug formulary policies reflect evidence of value?

Suchergebnisse filtern